DSM Pharmaceutical Products appoints a new CEO and President.
DSM Pharmaceutical
Products, the contract manufacturing organization of Royal DSM, appointed Lukas Utiger, PhD as its new CEO and President, effective Oct. 1, 2013.
Headquartered in Parsippany, NJ, the DSM Pharmaceutical Products business group includes DSM Biologics/BioSolutions, DSM Pharma Chemicals, DSM Exclusive Synthesis & Intermediates, and DSM Pharmaceuticals with operations in the US, Europe, and Australia.
Utiger has 25 years of industry experience, managing both small- and large-molecule manufacturing, as well as research and development.
Prior to joining DSM, Utiger was responsible for Lonza’s Bioscience division, where for more than 10 years he also served on the executive committee for various divisions including the pharma contract manufacturing organization and nutrition.
Source:
DSM Pharmaceutical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.